"The Chinese Dragon strikes again," says small cap expert Jim Oberweis, Jr., adding, "So far in 2009, the MSCI China Index is up 30% and our Oberweis China Opportunities Fund (OBCHX) has gained 62%."

In his The Oberweis Report, he says, "China will be a great place to invest over the medium-to-long term, even if unpredictable in the short term."

Here, the advisor and money manager reveals four stocks that he considers "some of the most interesting Chinese ADRs to buy now: E-House (NYSE: EJ), Asia Info Holdings (NASDAQ: ASIA), New Oriental Education (NYSE: EDU), and Longtop Financial (NYSE: LFT).

Continue reading China expert picks four favorite ADRs

China expert picks four favorite ADRs originally appeared on BloggingStocks on Mon, 22 Jun 2009 12:00:00 EST. Please see our terms for use of feeds.

"Genomics may be the 'next big thing' after the Internet and biotech. Finding those who can make money early onwill likely pay dividends to investors," expla]in small cap growth stock specialist Jim Oberweis, Jr.

In his The Oberweis Report, he explains the "politics" behind this bullish scenario as well as his top pick for log-term investors seeking exposure to the developing healthcare technologies if genomics and personalized medicine.

"We believe that the biotech boom was a direct consequence of rising National Health Institute (NIH) funding, cheap equity capital, and the ability to patent NIH-funded discoveries. And we see that happening again.

Continue reading Genomics: The next big thing?

Genomics: The next big thing? originally appeared on BloggingStocks on Mon, 18 May 2009 14:00:00 EST. Please see our terms for use of feeds.

In The Oberweis Report, growth expert Jim Oberweis. Jr. sees upside for risk-oriented investors in two diagnostics firms: Myriad Genetics (NASDAQ: MYGN) and Thoratec (NASDAQ: THOR).

"Myriad develops molecular diagnostic products focused in the area of predictive caner diagnostics. It currently sells five genetic tests (and just recently announced the launch of a 6th test in December) focused on cancer and women's health.

"The bulk of their revenues currently come from their BRACAnalysis test for breast cancer. This test is the only one of its kind available to detect a faulty version of BRAC genes in women, which has been linked to significantly increased chances of developing breast and ovarian cancers.

Continue reading Diagnostics duo: Myriad (MYGN) and Thoratec (THOR)

Diagnostics duo: Myriad (MYGN) and Thoratec (THOR) originally appeared on BloggingStocks on Tue, 17 Mar 2009 10:30:00 EST. Please see our terms for use of feeds.

Over 32 years, the portfolio in The Oberweis Report has returned an average gain of 21.2% a year vs. 7.9% for the S&P 500. Here, money manager and newsletter advisor Jim Oberweis, Jr. looks at Suntech Power Holdings Ltd. (NYSE: STP).

"Long-term results notwithstanding, 2008 has been humbling, to say the least. No other year in our history has been as challenging.

"But in our experience, the most favorable buying opportunities tend to fall after a period in which the market has not performed well.

"Although year-by-year results can be volatile, disciplined investors who remain fully invested in a portfolio of high-growth equities selected using our methodology have historically achieved an exceptional average rate of return over long periods of time.

"Suntech Power Holdings Co., Ltd is one of the leading solar energy companies in the world as measured by production output of photovoltaic, or PV, cells, with leading positions in key solar markets such as Germany and Spain.

Continue reading Suntech (STP) Solar shines for small cap expert

Suntech (STP) Solar shines for small cap expert originally appeared on BloggingStocks on Mon, 20 Oct 2008 12:27:00 EST. Please see our terms for use of feeds.

Each year Steven Halpern, editor of TheStockAdvisors.com, surveys the leading financial newsletter advisors asking for their favorite stocks for the coming year. This article is part of his 24th annual Top Picks Report.

Tessera Technologies (NASDAQ: TSRA) is a favorite speculative idea for 2007 from Jim Oberweis, editor of The Oberweis Report. The small-cap growth advisor explains, "We screen for companies that are delivering accelerating earnings and sales growth rates -- and ideally those that are not widely followed by Wall Street.

"Tessera develops semiconductor packaging technology that allows semiconductor manufacturers to miniaturize the chip and to improve performance. The San Jose, California, company has signed license agreements with manufacturers representing 80% of the worldwide dynamic random access memory (DRAM) market, including Micron Technology and Samsung Electronics.

"DRAM in personal computers is shifting to DDR2 DRAM, which utilizes TSRA's packaging technology, and DDR2 is expected to represent roughly 75% of DRAM shipments in 2007. TSRA receives a per unit royalty for each DDR2 DRAM shipped by their licensees.

"For the quarter ended September 30, 2006, Tessera posted an 841% jump in earnings per share on a 460% rise in revenue. I believe that Wall Street's consensus estimate for revenue ($198.8MM) and earnings per share ($1.08) for 2007 are too low. Lower litigation expenses in 2007 as patent litigation subsides should drive operating margin expansion as well."

Top Picks 2007: Oberweis expects high growth for Tessera originally appeared on BloggingStocks on Mon, 25 Dec 2006 08:30:00 EST. Please see our terms for use of feeds.